🚨 Your competitive intelligence team may be working, but are they actually winning?
If your team is still reading PACER by hand, the cost isnt just timeits momentum. In pharma and biotech, the companies that move fastest dont just react sooner. They…

Patents dont end on a calendar. Thats why generic launch dates never behave.
Theres a comfortable myth in pharma planning: that patent expiration is a reliable countdown to generic competition.
In the real world, it rarely works that way.
The three-clo…

The patent cliff is one of those phrases that sounds so decisivelike a switch flips, revenues tumble, and generic competition storms the gates.
But reality is rarely that clean.
A new post from DrugPatentWatch argues that the patent cliff is more myth …

Big drugs dont lose because theyre weak.
They lose because the right people never showed up.
Thats the subtext of the latest analysis from DrugPatentWatch: in blockbuster pharma, the real patent isnt always the headline-grabbing one. Often, the decisiv…

Strong IP Doesnt Win in CourtEnforceable IP Does
Its a comforting myth in life sciences: if your patents are strong, the courtroom will do the rest.
But in practice, strength is not a marketing term. Its a legal oneand courts dont reward confidence. Th…

Pharma executives keep using a familiar phraseloss of exclusivityto describe what happens when a brand faces generic or biosimilar entry. It sounds clinical. It sounds objective. It sounds inevitable.
But heres the uncomfortable truth: for most drugs, …

The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation
Patent litigation in pharma can look like an arms racebig law firms, aggressive pleadings, and endless motion practice. But in the trenches, the decisive advantage o…

Most drug patent fights are decided before the courtroom ever opens.
In theory, the legal system rewards right. In practice, drug patent litigation is often won by the side that did the better work product first: better prior art searching, better clai…

The Authorized Generic Strategy: How Brands Can (Quietly) Beat the Patent Cliff
The patent cliff is supposed to be a countdown to price erosion.
But in pharma, timelines are often suggestionsand competition doesnt always arrive the way investors expect…

Most investors assume the patent cliff story is simple: if a drug is protected, returns follow; if protection ends, revenues fall. Reality is messierand the gap between a truly defensible drug patent and a listed patent can be wider than most portfolio…